Drug combination

Cervical Dysplasia Market is expected to generate a revenue of USD 789.32 Million by 2030, Globally, at 7% CAGR: Verified Market Research®

Retrieved on: 
Monday, January 30, 2023
Conditional sentence, Dickinson, USD, Quest Diagnostics, Diagnosis, Midsayap Diagnostic Center and Hospital, Vulvectomy, Cervical intraepithelial neoplasia, Government, Minerva Surgical, Inc. v. Hologic, Inc., Drug combination, Woman, QIAGEN, Cancer, Geography, Cervical cancer, Hospital, Mortality, Test management, Research, Projection, Retail, Medical device, Birth control

JERSEY CITY, N.J. , Jan. 30, 2023 /PRNewswire/ -- Verified Market Research® recently published a report, "Cervical Dysplasia Market" By Diagnostic (Diagnostic Tests, Diagnostic Devices), By End-User (Hospitals, Diagnostic Centers), and By Geography.

Key Points: 
  • JERSEY CITY, N.J. , Jan. 30, 2023 /PRNewswire/ -- Verified Market Research® recently published a report, " Cervical Dysplasia Market " By Diagnostic (Diagnostic Tests, Diagnostic Devices), By End-User (Hospitals, Diagnostic Centers), and By Geography.
  • The "Global Cervical Dysplasia Market" is mainly bifurcated into sub-segments which can provide classified data regarding the latest trends in the market.
  • The "Global Cervical Dysplasia Market" study report will provide valuable insight with an emphasis on the global market.
  • Ltd, OncoHealth Corporation, Inc., and Hologic, Inc.
    Based on the research, Verified Market Research® has segmented the global Cervical Dysplasia Market into Diagnostic, End-User, and Geography.

Cervical Dysplasia Market is expected to generate a revenue of USD 789.32 Million by 2030, Globally, at 7% CAGR: Verified Market Research®

Retrieved on: 
Monday, January 30, 2023
Conditional sentence, Dickinson, USD, Quest Diagnostics, Diagnosis, Midsayap Diagnostic Center and Hospital, Vulvectomy, Cervical intraepithelial neoplasia, Government, Minerva Surgical, Inc. v. Hologic, Inc., Drug combination, Woman, QIAGEN, Cancer, Geography, Cervical cancer, Hospital, Mortality, Test management, Research, Projection, Retail, Medical device, Birth control

JERSEY CITY, N.J., Jan. 30, 2023 /PRNewswire/ -- Verified Market Research® recently published a report, "Cervical Dysplasia Market" By Diagnostic (Diagnostic Tests, Diagnostic Devices), By End-User (Hospitals, Diagnostic Centers), and By Geography.

Key Points: 
  • JERSEY CITY, N.J., Jan. 30, 2023 /PRNewswire/ -- Verified Market Research® recently published a report, " Cervical Dysplasia Market " By Diagnostic (Diagnostic Tests, Diagnostic Devices), By End-User (Hospitals, Diagnostic Centers), and By Geography.
  • The "Global Cervical Dysplasia Market" is mainly bifurcated into sub-segments which can provide classified data regarding the latest trends in the market.
  • The "Global Cervical Dysplasia Market" study report will provide valuable insight with an emphasis on the global market.
  • Ltd, OncoHealth Corporation, Inc., and Hologic, Inc.
    Based on the research, Verified Market Research® has segmented the global Cervical Dysplasia Market into Diagnostic, End-User, and Geography.

Global Ovarian Cancer Drugs Market Report 2022-2027: Analysis by Alkylating Agents, Mitotic Inhibitors, Antirheumatics, Antipsoriatics, VEGF/VEGFR Inhibitors, PARP Inhibitors, & Antineoplastics

Retrieved on: 
Monday, January 23, 2023
Cancer Research UK, Female, III, Paclitaxel, Incidence, Ovarian cancer, National Cancer Institute, BRCA1, Life, Malignancy, Environment, Fatality, Bevacizumab, Government, Liver, Drug combination, American Cancer Society, FDA, Bloating, Growth, Cancer, Somatic symptom disorder, Breast, BRCA2, Prevalence, Market, Pelvic pain, Surveillance, API, Roche, Cell proliferation, Organization, Woman, Lymph, Risk, Carboplatin, SEER, Research, Pharmaceutical industry, Birth control, Epidemiology

The global ovarian cancer drugs market is anticipated to witness an impressive growth during the forecast period, 2023-2027

Key Points: 
  • The global ovarian cancer drugs market is anticipated to witness an impressive growth during the forecast period, 2023-2027
    Ovarian Cancer is one of the most severe and common cancer that affects the women these days.
  • According to the American Cancer Society estimations, the inherited genetic factors contribute to about 10% of occurrences of ovarian cancer.
  • The market for ovarian cancer drugs is growing in a highly favourable environment due to the recent increase in ovarian cancer cases.
  • Company Profiles: Detailed analysis of the major companies present in global ovarian cancer drugs market.

The GastroIntestinal Research Foundation Awards Grants to Two Cancer Research Powerhouses

Retrieved on: 
Tuesday, January 24, 2023
Fatty liver disease, BRAF, Research, DNA, Science, DNA repair, Anderson, Immunotherapy, Cancer, Moses Austin, Vaccine, Survival, Therapy, DRS, Drug combination, Mayo Clinic, Immune system, CAR, University, Patient, Colorectal cancer, Neoplasm, Degenerative disease, Clinical trial, FDA, Ulcerative colitis, Precision medicine, Workflow, CRC, Monroe Dunaway Anderson, Biology, Crohn's disease, Toxicity, Pharmaceutical industry

The GastroIntestinal Research Foundation (the Foundation) has made bold and innovative grant awards to advance the development of immunotherapies and personalized vaccines for colorectal cancer.

Key Points: 
  • The GastroIntestinal Research Foundation (the Foundation) has made bold and innovative grant awards to advance the development of immunotherapies and personalized vaccines for colorectal cancer.
  • The Foundation's Executive Director, Jackie Casey, said, "The Foundation designed CA CURE to get vital research dollars quickly into the hands of investigators.
  • With focused funding on immunotherapies and vaccines and by taking multiple shots on goal with multiple research grants, we hope to see new successful treatments on the horizon."
  • We are grateful for the GI Research Foundation grant as it will allow us to take successes in the study of other cancers and apply them to colorectal cancer."

Global Ovarian Cancer Drugs Market Analysis Report 2022-2027: Ovarian Cancer Drugs Sector will Soon Experience Significant Growth in Developed Nations - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 19, 2023
Health, Oncology, Ovarian cancer, National Cancer Institute, American Cancer Society, Roche, Bevacizumab, Symptoms of COVID-19, BRCA1, Pelvic pain, Government, Cell proliferation, Breast, Malignancy, FDA, Surveillance, Risk, Environment, Carboplatin, Bloating, Organization, Woman, API, Growth, SEER, Prevalence, BRCA2, Lymph, Research, Cancer, Cancer Research UK, Liver, Fatality, Drug combination, III, Incidence, Market share, Life, Paclitaxel, Female, Pharmaceutical industry, Birth control, Dietary supplement, Epidemiology

According to the American Cancer Society estimations, the inherited genetic factors contribute to about 10% of occurrences of ovarian cancer.

Key Points: 
  • According to the American Cancer Society estimations, the inherited genetic factors contribute to about 10% of occurrences of ovarian cancer.
  • The market for ovarian cancer drugs is growing in a highly favourable environment due to the recent increase in ovarian cancer cases.
  • Therefore, it is anticipated that the ovarian cancer drugs sector will soon experience significant growth in developed nations.
  • Company Profiles: Detailed analysis of the major companies present in global ovarian cancer drugs market.

Baylor Scott & White Research Institute, TGen and OncoHost Announce New Research Study to Analyze Resistance Mechanisms in Lung Cancer

Retrieved on: 
Tuesday, January 10, 2023
Lung cancer, Urine, Blood, Element, Protein, Translational Genomics Research Institute, Baylor University Medical Center, MD, Research, Hope, City, DNA, Probability, Disease, Patient, Baylor Scott & White Medical Center – Temple, PD-L1, City of Hope, Cell biology, Biomedical Research, Drug combination, Genetics, RNA, Cell, Proteomics, Pharmaceutical industry, Medical imaging, Immunology, PHOENIX, Cancer, DALLAS

DALLAS, PHOENIX, and BINYAMINA, Israel, Jan. 10, 2023 /PRNewswire/ -- Baylor Scott & White Research Institute, the research arm of Baylor Scott & White Health; the Translational Genomics Research Institute (TGen), part of City of Hope, a nonprofit biomedical research center; and OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, today announced a new research study.

Key Points: 
  • Prospective study aimed at analyzing cancer resistance mechanisms using several multiomics technologies with a follow-up period of up to five years.
  • DALLAS, PHOENIX, and BINYAMINA, Israel, Jan. 10, 2023 /PRNewswire/ -- Baylor Scott & White Research Institute, the research arm of Baylor Scott & White Health; the Translational Genomics Research Institute (TGen), part of City of Hope, a nonprofit biomedical research center; and OncoHost , a global leader in next-generation precision oncology for improved personalized cancer therapy, today announced a new research study.
  • "We're excited to collaborate with OncoHost and TGen on this study and monitor its findings over the next five years.
  • "It's an honor to collaborate with TGen and Baylor Scott & White Research Institute, both of which are prestigious research organizations.

Curesponse shows applicability of next generation Immuno-oncology drugs in the pan-cancer cResponse system

Retrieved on: 
Wednesday, December 21, 2022
NGS, Cancer, Patient, CE, Neoplasm, ESMO, Architecture, Mouse Models of Human Cancer database, Drug combination, TME, Oncology, Congress, Lung, 3D, Research, Medical imaging, EU

The data presented shows the capacity of T-Cells to undergo activation and cancer tissue recruitment when stimulated using an immuno-oncology compound, in colorectal, lung and pancreatic cancer.

Key Points: 
  • The data presented shows the capacity of T-Cells to undergo activation and cancer tissue recruitment when stimulated using an immuno-oncology compound, in colorectal, lung and pancreatic cancer.
  • Curesponse is a commercial stage precision oncology start up, maker of the cResponse platform, an AI-driven, functional-genomics drug prioritization technology.
  • The company is collaborating with leading pharma partners, offering cResponse as a more timely and predictive drug development platform.
  • In addition, the cResponse test is CE marked and is routinely reimbursed by private payers in Israel for personalized cancer treatment decision guidance.

Curesponse shows applicability of next generation Immuno-oncology drugs in the pan-cancer cResponse system

Retrieved on: 
Wednesday, December 21, 2022
NGS, Cancer, Patient, CE, Neoplasm, ESMO, Architecture, Mouse Models of Human Cancer database, Drug combination, TME, Multimedia, Oncology, Congress, Lung, 3D, Research, Medical imaging, EU

The data presented shows the capacity of T-Cells to undergo activation and cancer tissue recruitment when stimulated using an immuno-oncology compound, in colorectal, lung and pancreatic cancer.

Key Points: 
  • The data presented shows the capacity of T-Cells to undergo activation and cancer tissue recruitment when stimulated using an immuno-oncology compound, in colorectal, lung and pancreatic cancer.
  • Curesponse is a commercial stage precision oncology start up, maker of the cResponse platform, an AI-driven, functional-genomics drug prioritization technology.
  • The company is collaborating with leading pharma partners, offering cResponse as a more timely and predictive drug development platform.
  • In addition, the cResponse test is CE marked and is routinely reimbursed by private payers in Israel for personalized cancer treatment decision guidance.

Alto Neuroscience Announces Positive Data from Phase 1 Study Evaluating Brain Effects of Novel Drug Combinations

Retrieved on: 
Wednesday, December 14, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Memory, Therapy, Camp, Pharmacology, Genetics, Biomarker, Patient, Alertness, Biology, PTSD, Memorial Day, Neuroscience, Attention, Human, EEG, Brain, Volunteering, ERP, Depression, Cognition, Drug combination, Pharmaceutical industry, Typesetting

Novel drug combinations, ALTO-103 and ALTO-104, exhibited significant pharmacodynamic effects compared to placebo on measures associated with therapeutic response in patients.

Key Points: 
  • Novel drug combinations, ALTO-103 and ALTO-104, exhibited significant pharmacodynamic effects compared to placebo on measures associated with therapeutic response in patients.
  • We discovered these novel combinations based on the concept of synergistic pharmacology drugs whose effects intersect on common signaling pathways in the brain.
  • The potential of our novel combination approach for driving key brain circuitry more powerfully and specifically hits on a largely untapped therapeutic strategy.
  • In evaluating the effects of the product candidates, the data was separated into a training and holdout data set to prospectively test and replicate observed effects.

Cellworks Biosimulation Study Reveals Biomarkers That Predict Response to Hypomethylating Agents and Patient Survival in MDS

Retrieved on: 
Monday, December 12, 2022
Software, Research, General Health, Pharmaceutical, Data Management, Oncology, Technology, Genetics, Clinical Trials, Science, Biotechnology, Health, Other Science, Leukemia Research, HOXA9, Lymphatic system, CEBPA, Software, Biosimulation, Society, Research, Methylation, Disease, Patient, DS, SPI1, Pearson, EZH2, Myelodysplastic syndrome, AML, MDS, Drug combination, Prognosis, Decitabine, City, University of Tennessee Health Science Center, University, DNMT3A, Abstract, Survival, NR, R, MD, Leukemia, Diagnosis, CBL, CBM, UnitedHealth Group, Student, TP53, Sequoia Capital, HMA, ASH, Versata Development Group, Inc. v. SAP America, Inc., Master of Science, Exposition, Chair, NF1, ITGAM, Haematopoietic system, Biomarker, RUNX1, Neuro, GATA1, Blood, Hypomethylating agent, NRAS, Medical imaging, Pharmaceutical industry, Hematology

In the study, DS predicted HMA response in MDS patients and showed a strong correlation to the treatment efficacy score (ES).

Key Points: 
  • In the study, DS predicted HMA response in MDS patients and showed a strong correlation to the treatment efficacy score (ES).
  • This study demonstrates the power of using Cellworks personalized therapy biosimulation to gain insight into individual patient mutanome, drug resistance pathways and novel biomarkers that determine their drug response and resistance to better inform treatment decisions for MDS patients.
  • This study shows that Cellworks personalized therapy biosimulation, which was based on each patients genomic aberrations, reveals a high spectrum of DS among patients with MDS.
  • The Cellworks Platform predicts therapy response for individual patients and patient cohorts using a breakthrough Computational Biology Model (CBM) and biosimulation technology.